Quotient Clinical hosts formulation development and drug delivery seminar series
Quotient Sciences is holding a series of formulation development and drug delivery seminars this June and July. The seminars will take place at major life science hubs in the UK and USA, and will address the most pressing challenges currently faced by pharmaceutical and biotechnology companies in early drug development.
Quotient Clinical showcases Human ADME studies and applications at ISSX 2016
Quotient Sciences will present two poster publications at the forthcoming 11th International ISSX Meeting 2016 in Busan, South Korea. The poster publications describe recent advancements in the design of integrated clinical programs to generate pivotal pharmacokinetic and metabolism data addressing key development and regulatory requirements.
Ironshore Pharmaceuticals enters into an agreement with Quotient Clinical to conduct scintigraphy imaging of a new drug candidate
Agreement with Quotient Clinical Expands Pipeline Beyond Neuroscience Franchise Proof of Concept Study Designed to Demonstrate Preferential Delivery of Drug to Initial Site of Damage in IBD to Position HLD-400 as Potential First-Line Therapy.
Quotient Clinical and Upperton announce a spray drying partnership to deliver integrated formulation development and GMP manufacturing programs for poorly soluble drugs
Quotient Sciences, the Translational Pharmaceutics® company, and Upperton, the UK spray drying specialist, have announced a partnership to address drug delivery challenges. This venture willcombine Upperton’s formulation development services with Quotient’s GMP manufacturingservices.
Quotient Clinical wins BVCA Management Team Award
Quotient Sciences is delighted to receive a BVCA Management Team Award in the category of “Large Company”. The Award was presented to CEO Mark Egerton and CFO Gordon Cameron at last night’s annual BVCA Midlands Dinner in Birmingham. Now in its eighth year, the BVCA Management Team Awards recognise and reward the achievements and success.